Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Capital Employed: 2019-2025

Historic Return on Capital Employed for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to -0.74%.

  • BridgeBio Pharma's Return on Capital Employed rose 18.00% to -0.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.74%, marking a year-over-year increase of 18.00%. This contributed to the annual value of -1.03% for FY2024, which is 35.00% up from last year.
  • BridgeBio Pharma's Return on Capital Employed amounted to -0.74% in Q3 2025, which was up 9.07% from -0.82% recorded in Q2 2025.
  • BridgeBio Pharma's Return on Capital Employed's 5-year high stood at -0.53% during Q2 2021, with a 5-year trough of -1.33% in Q4 2023.
  • For the 3-year period, BridgeBio Pharma's Return on Capital Employed averaged around -0.96%, with its median value being -0.92% (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Return on Capital Employed crashed by 41bps in 2023, and later soared by 43bps in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Return on Capital Employed stood at -0.76% in 2021, then fell by 17bps to -0.92% in 2022, then tumbled by 41bps to -1.33% in 2023, then spiked by 40bps to -0.93% in 2024, then increased by 18bps to -0.74% in 2025.
  • Its Return on Capital Employed stands at -0.74% for Q3 2025, versus -0.82% for Q2 2025 and -0.93% for Q1 2025.